Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: GOG 9927: A PHASE I TRIAL OF PEGYLATED LIPOSOMAL DOXORUBICIN (PLD), CARBOPLATIN AND NCI SUPPLIED VELIPARIB (ABT-888) IN RECURRENT PLATINUM SENSITIVE OVARIAN, PRIMARY PERITONEAL AND FALLOPIAN TUBE CANCER

 


GOG 9927: A PHASE I TRIAL OF PEGYLATED LIPOSOMAL DOXORUBICIN (PLD), CARBOPLATIN AND NCI SUPPLIED VELIPARIB (ABT-888) IN RECURRENT PLATINUM SENSITIVE OVARIAN, PRIMARY PERITONEAL AND FALLOPIAN TUBE CANCER


Trial Focus

Ovarian Cancer

Objective

         This is a clinical trial of Veliparib (ABT-888) that will be administered by mouth and is investigational, of Pegylated Liposomal Doxorubicin (PLD) that will be administered by IV which is standard of care, and of Carboplatin administerdy by IV which is s

IRB Protocol #

12-1011

Trial Status

Archived

Principle Investigator

SUSAN DAVIDSON

Sponsor

GOG

Contact

REBECCA KISSANE at (720)848-7202 or REBECCA.KISSANE@UCDENVER.EDU

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period to determine eligibility. A treatment period(s) that can last as long as there is evidence that the tumor is not growing and you are not experiencing any unacceptable side effects. A follow up period will consist of physician contact and clinic visits. // Eligibility criteria include but are not limited to 18 years or older with ovarian, primary peritoneal or fallopian tube cancer that has re-grown after prior treatment.Eligibility criteria include but are not limited to 18 years or older with ovarian, primary peritoneal or fallopian tube cancer that has re-grown after prior treatment.